Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Core Insights - Guardant Health, in collaboration with Mayo Clinic, published the largest study to date on circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in resected stage III colon cancer patients, indicating that ctDNA detection is a better predictor of recurrence and overall survival compared to standard staging [1][2] Group 1: Study Findings - Approximately 20% of patients in the phase III trial had detectable ctDNA post-surgery, with Guardant Reveal identifying a four-to-six-fold higher rate of disease recurrence or reduced survival [2] - Patients with smaller tumors or fewer affected lymph nodes also showed over a six-fold higher rate of events when ctDNA was detected, supporting the integration of ctDNA testing into routine postoperative management [2][4] Group 2: Clinical Implications - The amount of ctDNA, known as tumor fraction, further distinguishes patients at the highest risk of early recurrence and worse survival, aiding clinicians in prioritizing intensive surveillance or alternative therapies [3][4] - ctDNA testing enhances the accuracy of estimating cancer recurrence risk, allowing for more tailored recommendations for adjuvant chemotherapy and follow-up monitoring [4] Group 3: Company Overview - Guardant Health is a leading precision oncology company focused on providing insights into disease drivers through advanced blood and tissue tests, real-world data, and AI analytics, aiming to improve outcomes across all stages of cancer care [5] - The company has expanded its Reveal test to support late-stage therapy response monitoring, reinforcing its clinical utility in molecular residual disease and personalized care [4]